Stay updated on RVT-1401 Study in Myasthenia Gravis Patients Clinical Trial

Sign up to get notified when there's something new on the RVT-1401 Study in Myasthenia Gravis Patients Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the RVT-1401 Study in Myasthenia Gravis Patients Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:53:27.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the reduction of total IgG and anti-AChR-IgG levels in Myasthenia Gravis patients following treatment with RVT-1401 compared to placebo in a Phase 2a clinical study.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:08.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying age, health condition, and prior treatments required for inclusion. Previously, no information was provided under Participation Criteria.
    Difference
    18%
    Check dated 2024-05-22T21:02:14.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:19:12.000Z thumbnail image

Stay in the know with updates to RVT-1401 Study in Myasthenia Gravis Patients Clinical Trial

Enter your email address, and we'll notify you when there's something new on the RVT-1401 Study in Myasthenia Gravis Patients Clinical Trial page.